Publikationen, Projekte & klinische Studien

• Publikationen
• aktuelle Projekte
• klinische Studien in der Schweiz

Publikationen

Folgende Arbeiten der Studiengruppe wurden bisher publiziert:

• Graf JR, Forster S, Bruehl FK, Banz Y, Hallal M, Brodard J, Bacher VU, Allam R, Schürch CM, Bonadies on behalf of the Swiss MDS Study Group N. Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes.
  Cancers. 2021; 13(22):5712.

• Chanias I, Stojkov K, Stehle GT, Daskalakis M, Simeunovic H, Njue LM, Schnegg-Kaufmann AS, Porret NA, Allam R, Rao TN, Benz R, Ruefer A, Schmidt A, Adler M, Rovo A, Balabanov S, Stuessi G, Bacher U, Bonadies N on behalf of the Swiss MDS Study Group.
  Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.
  Cancers 2021, 13, 3296.

• Bonadies N, Rovó A, Porret N, Bacher U.
  When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.
  J Clin Med. 2021 Mar 2;10(5):1026

• Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R.
  Outcome of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
  Lancet Haematol. 2021 Feb;8(2):e135-e148

• Chanias I, Wilk CM, Benz R, Daskalakis M, Stüssi G, Schmidt A, Bacher U, Bonadies N, On Behalf Of The Swiss Mds Study Group.
  Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement.
  Int J Environ Res Public Health. 2020 Dec 21;17(24):9562

• Chanias I, Bonadies N
  Current Standard of Care in Patients with Myelodysplastic Syndromes and Future Perspectives
  healthbook TIMES Onco Hema 2020;(6):10–22

• Kasprzak A, Nachtkamp K, Kondakci M, Schroeder T, Kobbe G, Kündgen A, Kaivers J, Rautenberg C, Haas R, Gattermann N, Bonadies N, Germing U.
  Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes.
  Ann Hematol. 2021 Feb;100(2):455-463

• Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Čermák J, Dinmohamed AG, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies N.
  Guideline-based indicators for adult patients with myelodysplastic syndromes.
  Blood Adv. 2020 Aug 25;4(16):4029-4044

• Engelbrecht L, Götze KS, Schwamborn K, Alpermann T, Bonadies N, Legros M, Flach J, Pabst Th, Banz Y, Bacher U.
  Correlation of cytomorphology and histopathology in the diagnostic process of myeloid malignancies
  Hematol Med Oncol 4

• Bonadies N, Bacher V.U.
  What role can next-generation sequencing play in myelodysplastic syndrome care?
  Expert Rev Hematol. 2019 Jun;12(6):379-382
  

• Affentranger L, Bohlius J, Hallal M, Bonadies N.
  Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: a systematic review
  Crit Rev Oncol Hematol. 2019 Apr;136:37-47

• Benzarti S, Daskalakis M, Feller A, Bacher VU, Schnegg-Kaufmann A, Rüfer A, Holbro A, Schmidt A, Benz R, Solenthaler M, Stussi G, Arndt V, Bonadies N; NICER Working Group.
  Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
  Cancer Epidemiol. 2019 Apr;59:51-57
  

• Kipfer B, Daikeler T, Kuchen S, Hallal M, Andina N, Allam R, Bonadies N.
  Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
  Semin Hematol. 2018 Oct;55(4):242-247
  

• Silzle T, Bonadies N.
  Myelodysplastische Syndrome. WHO-Klassifikation und Einsatz der «Next-Generation»-Sequenzierung
  PPM MEDIC 2018 Mai; 22-27

• Shumilov E, Flach J, Kohlmann A, Banz Y, Bonadies N, Fiedler M, Pabst T, Bacher U.
  Current status and trends in the diagnostics of AML and MDS
  Blood Rev. 2018 Nov;32(6):508-519

• Ouahchi I, Zhang L, Benitez Brito R, Benz R, Müller R, Bonadies N, Tchinda J.
  Microarray-based comparative genomic hybridisation reveals additional recurrent aberrations in adult patients evaluated for myelodysplastic syndrome with normal karyotype
  Br J Haematol. 2019 Jan;184(2):282-287

• Bürki S, Shumilov E, Bonadies N, Flach J, Legros M, Banz Y, Oppliger-Leibundgut E, Fiedler M, Angelillo-Scherrer A, Rovo A, Bacher U.
  Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature
  Leuk Lymphoma. 2018 Sep;59(9):2233-2237
  

• Bonadies N.
  Management of Adult Patients with Myelodysplastic Syndromes
  EMJ Hematol. 2017;5[1]:104-112

• Bonadies N, Feller A, Rovo A, Ruefer A, Blum S, Gerber B, Stuessi G, Benz R, Cantoni N, Holbro A, Schmidt A, Lehmann T, Wilk CM, Arndt V; NICER Working Group.
  Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012
  Cancer Epidemiol. 2017 Feb;46:85-92

aktuelle Projekte

Nationale Working Packages (WPs):

• WP0: Swiss Survey on Myelodysplastic Syndromes’ Care Identifies Areas for Improvement (I. Chanias, Dr. M. Wilk, Prof. N. Bonadies). published

• WP1: I-CARE for MDS: Impact of Guidelines Adherence on Effectiveness and Safety of Health CARE Provided to MDS Patients (K. Stojkov, Dr. T. Silzle, Prof. N. Bonadies) O1: published, O2-O3: ongoing

  • WP1.1: Retro- und prospektive Analyse von ESA-assoziierten GBIs (M. Arnold, Prof. N. Bonadies)

• WP2: The Role of Innate Immunity in Chronic Myelomonocytic Leukaemia and Myelodysplastic Syndromes (Prof. R. Allam)
  

  • WP2.1: Expression of immunhistochemical markers for inflammasome activity and immune checkpoint inhibitors in MDS (J. Graf, Prof. N. Bonadies) published

  • WP2.2: Inflammassome Acivity in CMML patients (Dr. N. Andina, Prof. R. Allam) (manuscript in preparation)

• WP3: Exploration of the Influence of Free Plasma Iron Toxicity and Redox-Stress on Immune Subversion and Clonal Progression in Patients with Myelodysplastic Syndromes (Prof. N. Bonadies)

  • WP3.1: Validation of eLPI assay (A. Vella, Prof. N. Bonadies)

• WP4: Investigation of the role of cytomorphology and histopathology for the diagnosis of MDS in the era of modern genetics (Prof. U. Bacher) published
  

• WP5: The Role of Extracellular Vesicles in Myelodysplastic Syndromes (PD Dr. M. Heller) (manuscript in preparation)
  

• WP6: Characterization of Oncospecific Protein Isoforms as Targets for Myelodysplastic Syndromes (Prof. St. Balabanov, Prof. N. Bonadies)

• WP7: Evaluation of the utility of PROs in MDS and MDS/MPN patients (Dr. L. Njue, Prof. N. Bonadies)

  • WP7.1: Analysis of biomarkers for depression and fatigue (Dr. T. N. Rao)

• WP8: Retrospektiver Vergleich von MDS-Patienten jünger und älter als 50 Jahre (Dr. N Andina, Prof. N. Bonadies)

• WP9: Clinical characteristics and outcomes of hypoplastic MDS and AA in the real-world setting (B. Kaliyeva,  Prof. A. Rovo, Prof. N. Bonadies)

• WP10: Transition from CHIP to MDS (I. Chanias, Prof. N. Bonadies)

• WP11: The wolf in the sheeps clothing: LR-MDS with HR features (S. Affolter, H. Simeunovic, Prof. N. Bonadies)

• WP 12: MDS with autoinflammation (H. Simeunovic, Prof. N. Bonadies)

  • WP 12.1: MDS with VEXAS and other general autoinflammatory conditions  (Dr. F. Lötscher)
  • WP 12.2: Cutaneous manifestations in MDS and MDS/MPN (A. Carigiet, PD Dr. L. Feldmeyer)

• WP 13: Retrospektive Analyse der MDS-Kohorte des Universitätsspitals Basel der Jahre 2012 – 2017 (Dr. G. Stehle)

Internationale Kollaborationen (IPs):

• IP1: CMML First Line Treatment: PD. Dr. Lisa Pleyer, Salzburg Cancer Research, Austria (published)
• IP2: Genetic background of MDS-MPN-U:  Prof. Francesc Sole, Joseph Carrera Leukaemia Research Institute, Barcelona, Spain (ongoing)
• IP3: Genetic background of hypoplastic MDS:  Prof. Felicitas Thol, Hannover Medical School, Germany (ongoing)
• IP4: Guideline adherence in Düsseldorf MDS Registry. Prof. Ulrich Germing, Heinrich Heine University Düsseldorf Germany (published)

Klinische Studien in der Schweiz

In der Schweiz wird mit und ohne unserer Beteiligung an mehreren Studien über die MDS geforscht. Bei clinicaltrials.gov findet man eine weitere Übersicht über Studien mit Schweizer Beteiligung.